Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of iGlarLixi Versus iGlar on Liver Fat Content in Patients With Type 2 Diabetes Mellitus With Metabolic Dysfunction-associated Steatotic Liver Disease: A Randomized Controlled Trial

NCT07274644 is registered in ClinicalTrials.gov with The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School as lead sponsor.

NCT NCT07274644
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07274644 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of iGlarLixi Versus iGlar on Liver Fat Content in Patients With Type 2 Diabetes Mellitus With Metabolic Dysfunction-associated Steatotic Liver Disease: A Randomized Controlled Trial
Lead sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase
Phase 4
Overall status
Active, not recruiting
Start date
March 29, 2025
Completion date
July 30, 2026
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus type 2, metabolic dysfunction-associated steatotic liver disease